Cardiovascular Risk Stratification Using Inflammatory Age Scoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug treatment approaches for cardiovascular disease focus primarily on high-risk individuals and do not effectively address cardiovascular risk factors in the general population, particularly in asymptomatic individuals, as they rely on high levels of blood pressure or cholesterol rather than inflammatory markers.
Innovation Solution
A method based on inflammatory age scoring (iAge) and cytokine response score (CRS) to stratify individuals by their inflammatory levels, allowing for personalized interventions to reduce inflammatory factors and improve cardiovascular health, using markers such as MIG, LIF, and SIRT3 to classify risk and tailor treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drug treatment is used to control high blood pressure and cholesterol levels, then cardiovascular risk factors are reduced in high-risk individuals, but the approach does not effectively address cardiovascular risk in the general population or asymptomatic individuals
Solution Approach 1:
The patent changes the parameter used for risk stratification from traditional blood pressure and cholesterol levels to inflammatory markers (CRP, IL-6, TNF-alpha). This parameter change enables the treatment approach to be applied more broadly to the general population, including asymptomatic individuals, rather than only to those with clearly elevated traditional risk factors.
2Measurement precision
If treatment is given only to individuals with high blood pressure or cholesterol, then resource allocation is focused on clearly high-risk patients, but inflammatory risk factors in asymptomatic individuals are overlooked
Solution Approach 1:
The patent introduces inflammatory markers (CRP, IL-6, TNF-alpha) as intermediary indicators that bridge the gap between traditional risk factors and actual cardiovascular risk. These markers serve as mediators to identify individuals who may appear low-risk by traditional standards but actually have elevated inflammatory risk, thereby preventing loss of important risk information.
3Reliability
If lifestyle changes are implemented to reduce cardiovascular risk factors, then some improvement in risk factors is achieved, but the changes are generally not sufficient to substantially reduce cardiovascular risk
Solution Approach 1:
The patent implements preliminary identification of individuals with elevated inflammatory markers before they develop clinical cardiovascular disease. By detecting and treating high-inflammatory-risk individuals early, including asymptomatic persons, the system enables preventive intervention that can substantially reduce cardiovascular risk before disease manifestation, rather than waiting for traditional risk factors to become clearly elevated.
Data Source
AI summary
The methods and compositions described herein improve cardiovascular outcomes using measures related to systemic chronic inflammation (the inflammatory age—iAge, the cardiovascular age—cAge, and levels of certain markers) to stratify patients into low risk and high risk groups. The personalized immune proteome signature creates an individualized initial therapy to reduce cAge and to convert high risk patients into low risk patients. High risk patients can be converted to low risk patients by treating the patients to reduce their cAge, iAge and/or improve their CRS.